Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alpine Immune Sciences
Biotech
AbbVie agrees to end Alpine study early in return for fee cuts
Under the revised deal, Alpine will stop the study early—and accept a significantly reduced option fee if AbbVie chooses to pick up the lupus asset.
Nick Paul Taylor
Dec 22, 2023 5:40am
Lilly picks new head of diabetes, obesity unit—Chutes & Ladders
Oct 6, 2023 9:30am
Alpine bails on phase 1 cancer asset after 2nd patient death
Oct 24, 2022 11:30am
Forte taps new exec amid shareholder dissent—Chutes & Ladders
Jun 10, 2022 9:30am
Death in Alpine's Keytruda combo trial triggers clinical hold
Mar 7, 2022 9:18am
Up to $1.5B on the Horizon for Alpine in 4-drug biobucks pact
Dec 16, 2021 10:28am